中国癌症杂志 ›› 2018, Vol. 28 ›› Issue (8): 595-601.doi: 10.19401/j.cnki.1007-3639.2018.08.006

• 论著 • 上一篇    下一篇

非小细胞肺癌袖式切除术的预后分析

郑佳杰1,顾 畅1,罗继壮1,王奕洋1,陈海泉2   

  1. 1. 上海交通大学附属胸科医院,上海200030 ;
    2. 复旦大学附属肿瘤医院胸外科,复旦大学附属肿瘤医院肿瘤学系,上海 200032
  • 出版日期:2018-08-30 发布日期:2018-09-14
  • 通信作者: 陈海泉 E-mail:hqchen1@yahoo.com

Prognostic analysis of sleeve lobectomy for non-small cell lung cancer

ZHENG Jiajie1,GU Chang1, LUO Jizhuang1, WANG Yiyang1, CHEN Haiquan2   

  1. 1.Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030; 2. Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032
  • Published:2018-08-30 Online:2018-09-14
  • Contact: CHEN Haiquan E-mail:hqchen1@yahoo.com

摘要: 背景与目的:肺叶袖式切除术是一种针对中央型肺癌的手术,它保留正常肺组织从而尽可能保留患者的肺功能,同时,它也可以用于治疗因心肺的禁忌证而无法耐受全肺切除的患者。方法:我们针对接受肺叶袖式切除的非小细胞肺癌患者的肿瘤分期,对其预后情况进行了回顾性研究,从而判断此类手术的可行性。结果:患者手术后总生存率(overall survival,OS)为66.92%,无疾病生存率(disease-free survival ,DFS)为50.56 %。结论:通过本研究,我们发现肺叶袖式切除有较低的死亡率和并发症发生率。该手术可以保护患者的术后肺功能,可作为中央型非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的一种手术选择。

关键词: 肺叶袖式切除术, 总生存率, 无疾病生存率

Abstract: Background and purpose: Sleeve lobectomy is considered an acceptable surgery for patients with central lung cancer, and can preserve more lung functions because of the reservation of the normal lung tissues. It can also be an alternative surgery for patients with cardiac or pulmonary contraindications to pneumonectomy. Methods: In this study, we conducted a retrospective study to examine the safety and efficacy of sleeve lobectomy, particularly in relation with different stages. Results: In the group, the overall survival (OS) rate was 66.92%, and disease-free survival (DFS) rate was 18.4%. Conclusion: Sleeve lobectomy has low mortality and complication rates. It has good preservation of pulmonary function for tumor resection. It can be used as an alternative to pneumonectomy for patients with non-small cell lung cancer (NSCLC).

Key words: Sleeve lobectomy, Overall survival, Disease-free survival